Cargando…
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
BACKGROUND: The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment. METHODS: Nationwide population‐based data were retrieved from the Netherlands Cancer Registry. All patients w...
Autores principales: | van der Graaf, W. T. A., Tielen, R., Bonenkamp, J. J., Lemmens, V., Verhoeven, R. H. A., de Wilt, J. H. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033139/ https://www.ncbi.nlm.nih.gov/pubmed/29664995 http://dx.doi.org/10.1002/bjs.10809 |
Ejemplares similares
-
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012) -
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008) -
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
por: Giraud, Eline L., et al.
Publicado: (2023) -
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)